Zanubrutinib

FDA label information for this drug is available at DailyMed.

Use in Cancer

Zanubrutinib is approved to be used alone or with other drugs to treat adults with:

• Chronic lymphocytic leukemia or small lymphocytic lymphoma.
• Follicular lymphoma in patients who have received at least two types of systemic therapy but it did not work or is no longer working. It is used with obinutuzumab.¹
• Mantle cell lymphoma in patients who have received at least one other type of treatment.¹
• Marginal zone lymphoma in patients who have received at least one anti-CD20-based therapy but it did not work or is no longer working.¹
• Waldenström macroglobulinemia.

¹This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, a confirmatory trial(s) must show that zanubrutinib provides a clinical benefit in these patients.

Zanubrutinib is also being studied in the treatment of other types of cancer.

More About Zanubrutinib

Definition from the NCI Drug Dictionary – Detailed scientific definition and other names for this drug.

More About Zanubrutinib – A lay language summary of important information about this drug that may include the following:

• warnings about this drug,
• what this drug is used for and how it is used,
• what you should tell your doctor before using this drug,
• what you should know about this drug before using it,
• other drugs that may interact with this drug, and
• possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Research Results and Related Resources

Zanubrutinib’s Approval Improves Targeted Treatment for CLL

Targeted Cancer Therapies

Clinical Trials Accepting Patients

Find Clinical Trials for Zanubrutinib – Check for trials from NCI’s list of cancer clinical trials now accepting patients.